2024
DOI: 10.1080/16549716.2024.2305930
|View full text |Cite
|
Sign up to set email alerts
|

Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho

Lawrence Oyewusi,
Chengbo Zeng,
KJ Seung
et al.

Abstract: Background A low body mass index (BMI) at the start of treatment for rifampicin- or multidrug-resistant tuberculosis (MDR/RR-TB) is associated with poor treatment outcomes and may contribute to delayed sputum culture conversion, thereby prolonging the period of potential transmission to others. Whether the relative importance of low BMI in predicting treatment outcomes differs by HIV status is unclear. Objectives We evaluated the association between low BMI and two depe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 31 publications
(28 reference statements)
0
0
0
Order By: Relevance
“…However, the severity of the disease in this group of patients, coupled with the long treatment time, high treatment cost, and the increasing burden on the patient’s family, lead to a serious decline in the patient’s treatment adherence, thus affecting the clinical treatment effect and posing a threat to the patient’s quality of life and physical health[ 7 ]. As per the 2018 World Health Organization global TB report, the treatment success rate of patients with DR-TB is only 55% globally[ 8 ]. At present, the treatment of DR-TB mainly includes anti-TB drug therapy.…”
Section: Introductionmentioning
confidence: 99%
“…However, the severity of the disease in this group of patients, coupled with the long treatment time, high treatment cost, and the increasing burden on the patient’s family, lead to a serious decline in the patient’s treatment adherence, thus affecting the clinical treatment effect and posing a threat to the patient’s quality of life and physical health[ 7 ]. As per the 2018 World Health Organization global TB report, the treatment success rate of patients with DR-TB is only 55% globally[ 8 ]. At present, the treatment of DR-TB mainly includes anti-TB drug therapy.…”
Section: Introductionmentioning
confidence: 99%